DE60212365D1 - Medizinische zusammensetzungen zur behandlung oder vorbeugung eines funktionellen vitamin b12 mangels - Google Patents
Medizinische zusammensetzungen zur behandlung oder vorbeugung eines funktionellen vitamin b12 mangelsInfo
- Publication number
- DE60212365D1 DE60212365D1 DE60212365T DE60212365T DE60212365D1 DE 60212365 D1 DE60212365 D1 DE 60212365D1 DE 60212365 T DE60212365 T DE 60212365T DE 60212365 T DE60212365 T DE 60212365T DE 60212365 D1 DE60212365 D1 DE 60212365D1
- Authority
- DE
- Germany
- Prior art keywords
- administration
- vitamin
- cobalamin
- functional vitamin
- lack
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 title 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 abstract 2
- 230000003834 intracellular effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000002670 vitamin B12 deficiency Diseases 0.000 abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 1
- 108010024636 Glutathione Proteins 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000005864 Sulphur Substances 0.000 abstract 1
- 229930003779 Vitamin B12 Natural products 0.000 abstract 1
- 230000005856 abnormality Effects 0.000 abstract 1
- 230000008238 biochemical pathway Effects 0.000 abstract 1
- 238000011260 co-administration Methods 0.000 abstract 1
- 229960003180 glutathione Drugs 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000036542 oxidative stress Effects 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
- 239000011715 vitamin B12 Substances 0.000 abstract 1
- 235000019163 vitamin B12 Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0110336 | 2001-04-25 | ||
GB0110336A GB0110336D0 (en) | 2001-04-25 | 2001-04-25 | A method for treating an individual with metabolic evidence of Vitamid 12 deficiency and co-existing dementia or other neuropsychiatric abnormality |
GB0120363 | 2001-08-22 | ||
GB0120363A GB0120363D0 (en) | 2001-08-22 | 2001-08-22 | A method for treating an individual with low intracellular glutathione and/or metabolic evidence of vitamin B12 deficiency and co-existing dementia or other |
PCT/GB2002/001843 WO2002087593A1 (en) | 2001-04-25 | 2002-04-22 | A method for treating or preventing a functional vitamin b12 deficiency in an individual and to medical compositions for use in said method |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60212365D1 true DE60212365D1 (de) | 2006-07-27 |
DE60212365T2 DE60212365T2 (de) | 2007-05-31 |
Family
ID=26246012
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60212365T Expired - Lifetime DE60212365T2 (de) | 2001-04-25 | 2002-04-22 | Medizinische zusammensetzungen zur behandlung oder vorbeugung eines funktionellen vitamin b12 mangels |
Country Status (9)
Country | Link |
---|---|
US (2) | US7709460B2 (de) |
EP (1) | EP1381373B1 (de) |
JP (1) | JP2004526793A (de) |
CN (1) | CN1537009A (de) |
AT (1) | ATE329601T1 (de) |
CA (1) | CA2445512C (de) |
DE (1) | DE60212365T2 (de) |
ES (1) | ES2269671T3 (de) |
WO (1) | WO2002087593A1 (de) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10311089A1 (de) * | 2003-03-13 | 2004-09-23 | Roche Diagnostics Gmbh | Differenzialdiagnostik und Monitoring von Vitamin B12-, Vitamin B6- und Folsäure-Störungen mittels vier unabhängiger Messgrößen |
WO2006053010A2 (en) * | 2004-11-09 | 2006-05-18 | Hill's Pet Nutrition, Inc. | Use of antioxidants for gene modulation |
AR057623A1 (es) | 2005-11-28 | 2007-12-05 | Omega Bio Pharma H K Ltd | Materiales y metodos para el tratamiento de las infecciones virales |
PT1800675E (pt) | 2005-12-23 | 2011-08-30 | Nutricia Nv | COMPOSIÇÃO CONTENDO ÁCIDOS GORDOS POLI-INSATURADOS, PROTEÍNAS E MANGANjS E/OU MOLIBDÉNIO PARA O MELHORAMENTO DA COMPOSIÇÃO DA MEMBRANA |
US7754700B2 (en) * | 2006-04-24 | 2010-07-13 | Trager Seymour F | Composition and methods for alleviating symptoms of neurotoxicity |
CN101460159B (zh) * | 2006-06-07 | 2011-11-23 | 协和发酵生化株式会社 | 疲劳缓解剂 |
US7812042B2 (en) * | 2006-09-22 | 2010-10-12 | Kent State University | Pharmaceutical compositions and therapeutic applications for the use of a novel vitamin B12 derivative, N-acetyl-L-cysteinylcobalamin |
US7972633B2 (en) * | 2007-02-07 | 2011-07-05 | Applied Cognitive Sciences, LLC | Nutritional supplements for healthy memory and mental function |
GB0723972D0 (en) * | 2007-12-07 | 2008-01-23 | Queen Mary & Westfield College | Use of vitamin B12 |
WO2009158430A1 (en) | 2008-06-25 | 2009-12-30 | Iskandar Bermans S | (6s)-5-methyltetrahydrofolic acid for therapy of tissue injury |
CA3162668A1 (en) * | 2010-02-12 | 2011-08-18 | Gentelon, Inc. | Compositions and methods for treating depression |
EP2538945A4 (de) * | 2010-02-24 | 2013-07-24 | Emisphere Tech Inc | Orale b12-therapie |
EP2588198A1 (de) | 2010-07-01 | 2013-05-08 | Isis Innovation Limited | Behandlung von kognitiven störungen |
US9040082B2 (en) | 2011-06-24 | 2015-05-26 | K-Pax Pharmaceuticals, Inc. | Compositions and methods for treatment of chronic fatigue |
JP6015158B2 (ja) * | 2012-06-22 | 2016-10-26 | 大正製薬株式会社 | トランスコバラミンii遺伝子産物量調整剤 |
AU2016268340B2 (en) * | 2015-05-28 | 2021-07-08 | Baylor College Of Medicine | Benefits of supplementation with N-acetylcysteine and glycine to improve glutathione levels |
US20160367620A1 (en) | 2015-06-19 | 2016-12-22 | Harry B. Demopoulos | Glutathione |
WO2018144088A1 (en) | 2016-11-03 | 2018-08-09 | Alexander Vuckovic, M.D., Llc | Compositions and methods for treating depression |
EP3406622A1 (de) | 2017-05-24 | 2018-11-28 | Albert-Ludwigs-Universität Freiburg | Cobalaminderivate und deren verwendung zur behandlung von krankheiten durch mangelnde vitamin-b12-versorgung |
FR3068603B1 (fr) * | 2017-07-10 | 2020-01-03 | Nuribiol | Complement alimentaire pour proteger la fertilite feminine et masculine |
CA3086220A1 (en) | 2017-12-21 | 2019-06-27 | Osaka University | Therapeutic agent for nervous system disease |
US11216742B2 (en) | 2019-03-04 | 2022-01-04 | Iocurrents, Inc. | Data compression and communication using machine learning |
WO2021102053A1 (en) * | 2019-11-21 | 2021-05-27 | Lupin, Inc. | Vitamin b12 compound supplementation methods and compositions |
FR3119093B3 (fr) * | 2021-01-27 | 2023-02-10 | Nestle Sa | Compositions et procedes pour une utilisation dans l’augmentation de la performance motivationnelle |
US20220387474A1 (en) * | 2021-06-07 | 2022-12-08 | Peter Nagele | Supplement compositions for nitrous oxide patients |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US945772A (en) * | 1909-03-17 | 1910-01-11 | Hoard E | Mop. |
US3130189A (en) | 1959-04-06 | 1964-04-21 | Merck & Co Inc | Hydroxocobalamin-glutathione |
US4940658A (en) * | 1986-11-20 | 1990-07-10 | University Patents, Inc. | Assay for sulfhydryl amino acids and methods for detecting and distinguishing cobalamin and folic acid deficency |
US5807832A (en) * | 1987-06-09 | 1998-09-15 | Biotech Australia Pty Limited | Oral delivery of biologically active substances bound to vitamin B12 |
US5668117A (en) * | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
US6787527B1 (en) * | 1994-11-10 | 2004-09-07 | Duke University | Methods of preventing and treating HIV infection |
US6008190A (en) * | 1994-12-15 | 1999-12-28 | California Institute Of Technology | Cobalt Schiff base compounds |
US6274564B1 (en) | 1996-09-18 | 2001-08-14 | William J. Sarill | Compositions of cobalamin and related corrinoids, and uses thereof |
US6008221A (en) * | 1996-11-06 | 1999-12-28 | Bristol-Myers Squibb Company | Method for treating Alzheimer's disease with folic acid |
EP1007077B1 (de) * | 1997-01-13 | 2009-10-07 | Emory University | Glutathion zur behandlung von influenzainfektionen |
EP0891719A1 (de) * | 1997-07-14 | 1999-01-20 | N.V. Nutricia | Narungszusammensetzungen mit Gehalt an Methionin |
US6207190B1 (en) * | 1998-08-13 | 2001-03-27 | Chronorx, Llc | Dosage forms for the treatment of the chronic glaucomas |
ES2187115T3 (es) | 1999-01-20 | 2003-05-16 | Nutricia Nv | Preparado para lactantes. |
GB9906740D0 (en) | 1999-03-23 | 1999-05-19 | Kilgowan Limited | Oral combinations of hydroxocobalamin and folic acid |
US6649193B1 (en) * | 1999-06-11 | 2003-11-18 | Henceforth Hibernia Inc. | Prophylactic therapeutic and industrial antioxidant compositions enhanced with stabilized atomic hydrogen/free electrons and methods to prepare and use such compositions |
US6562869B1 (en) * | 1999-09-23 | 2003-05-13 | Juvenon, Inc. | Nutritional supplement for increased energy and stamina |
WO2001026642A2 (en) | 1999-10-08 | 2001-04-19 | Joyce Corinne Bechthold | Methods and compositions for treating neurobehavioral disorders |
DE10027968A1 (de) | 2000-06-08 | 2001-12-13 | Asta Medica Ag | Mittel zur Therapie von Demenzen |
US6812248B2 (en) * | 2000-07-05 | 2004-11-02 | John Hopkins University School Of Medicine | Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes |
-
2002
- 2002-04-22 EP EP02720247A patent/EP1381373B1/de not_active Expired - Lifetime
- 2002-04-22 AT AT02720247T patent/ATE329601T1/de active
- 2002-04-22 CA CA2445512A patent/CA2445512C/en not_active Expired - Fee Related
- 2002-04-22 DE DE60212365T patent/DE60212365T2/de not_active Expired - Lifetime
- 2002-04-22 ES ES02720247T patent/ES2269671T3/es not_active Expired - Lifetime
- 2002-04-22 WO PCT/GB2002/001843 patent/WO2002087593A1/en active IP Right Grant
- 2002-04-22 US US10/475,898 patent/US7709460B2/en active Active
- 2002-04-22 JP JP2002584938A patent/JP2004526793A/ja active Pending
- 2002-04-22 CN CNA028107241A patent/CN1537009A/zh active Pending
-
2010
- 2010-02-16 US US12/706,411 patent/US20110077194A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20040157783A1 (en) | 2004-08-12 |
EP1381373A1 (de) | 2004-01-21 |
JP2004526793A (ja) | 2004-09-02 |
US20110077194A1 (en) | 2011-03-31 |
US7709460B2 (en) | 2010-05-04 |
ES2269671T3 (es) | 2007-04-01 |
EP1381373B1 (de) | 2006-06-14 |
CA2445512A1 (en) | 2002-11-07 |
CA2445512C (en) | 2010-10-12 |
ATE329601T1 (de) | 2006-07-15 |
WO2002087593A1 (en) | 2002-11-07 |
CN1537009A (zh) | 2004-10-13 |
DE60212365T2 (de) | 2007-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60212365D1 (de) | Medizinische zusammensetzungen zur behandlung oder vorbeugung eines funktionellen vitamin b12 mangels | |
NO20050807L (no) | Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser | |
DE60331537D1 (de) | Kombinationen zur behandlung von multiplem myelom | |
DE60216830D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen | |
GB0201508D0 (en) | Organic compounds | |
CY1110353T1 (el) | Ανοσορρυθμιστικοι ολιγοσακχαριτες | |
ATE445405T1 (de) | Vorbeugung und behandlung von oxidativer-stress- erkrankungen mit verbindungen die den intrazellulären spiegel von glutathion oder phase-ii-entgiftungsenzymen erhöhen | |
BR0116370A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente. | |
NO20061245L (no) | Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og en bisfosfon | |
BRPI0416752A (pt) | composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica | |
BR0307508A (pt) | Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de tratamento de doença | |
BR0312232A (pt) | Inibidores de caspases e seus usos | |
ATE327747T1 (de) | Therapeutische kombination des ascorbats mit lysin und arginin für verhinderung und behandlung des krebses | |
DE59706808D1 (de) | Verwendung von 7-(2-oxa-5,8-diazabicyclo 4.3.0]non-8-yl)-chinoloncarbonsäure- und -naphthyridoncarbonsäure-derivaten zur herstellung eines arzneimittels zur therapie von helicobacter-pylori-infektionen und den damit assoziierten gastroduodenalen erkrankungen | |
WO2003030823A3 (en) | Combinations for the treatment of immunoinflammatory disorders | |
NO20061236L (no) | Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og paratyroidhoziiton | |
UY28098A1 (es) | Derivados de anilinopirazol útiles en el tratamiento de la diabetes | |
BR112022018645A2 (pt) | Composições e métodos para tratar ou prevenir doenças inflamatórias, incluindo diabetes mellitus tipo i e tipo ii e doenças da tireoide | |
DE69819110D1 (de) | Ein Arzneimittel zur Behandlung von Fettleibigkeit und Verbesserung des lipidmetabolismus | |
ATE293976T1 (de) | Verbindungen enthaltend s-tofisopam sowie verwendung dieser verbindungen zur herstellung eines medikamentes zur behandlung oder prophylaxe von krämpfen und anfällen | |
BR0311903A (pt) | Tratamento para depressão e ansiedade pela combinação de um inibidor de pde iv e um agente antidepressivo ou ansiolìtico | |
BRPI0407178A (pt) | Composição farmacêutica osteogênica | |
NO20044530L (no) | Fremgangsmate for behandling av kognitive forstyrrelser | |
DE3775854D1 (de) | Arzneimittel zur therapie von durch funktionelle und organische basen verursachten gehirnkrankheiten. | |
ATE364399T1 (de) | Einen zns-penetrierenden nk-1- rezeptorantagonisten und ein angstlösendes oder antidepressives mittel enthaltende zusammensetzung zur behandlung von depression und angst |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |